Loading stock data…
$1.73-0.04 (-2.54%)
Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States.
Processa Pharmaceuticals, Inc. in the Healthcare sector is trading at $1.73 with a market capitalization of $5M. The stock is currently near its 52-week low of $1.04, remaining 29.6% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 30/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$2.34M↑ | -$3.33M↑ | -$3.70M↓ | -$3.49M↑ | -$3.95M |
| Net Income | -$3.27M↑ | -$3.38M↓ | -$3.36M↑ | -$3.44M↑ | -$3.93M |
Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. The company's drugs are modifications of existing FDA-approved onco...